AAREYDRUGS vs PPLPHARMA: Stock Comparison

Aarey Drugs & Pharmaceuticals Limited vs Piramal Pharma Limited

Live data: 29 April 2026, 4:01 PM IST • Source: NSE and company filings

Piramal Pharma Limited is the larger company by market capitalisation. Aarey Drugs & Pharmaceuticals Limited shows a higher ROE, faster revenue growth and lower leverage, while Piramal Pharma Limited shows a lower P/E and a higher dividend yield. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.

Side-by-side comparison of Aarey Drugs & Pharmaceuticals Limited and Piramal Pharma Limited on live price, valuation, growth, profitability, leverage and quarterly shareholding. Highlighted values mark the more favourable of the two on that metric's usual reading; a single metric is never the full story.

On standard readings, AAREYDRUGS is more favourable on 9 of 13 scored metrics and PPLPHARMA on 4These counts are context-free and are not an overall rating.

Key Differences

Market Cap
PPLPHARMA is the larger company
₹23,554 Cr vs ₹221 Cr
P/E Ratio
PPLPHARMA has a lower P/E
-75.43x vs 55.36x
P/B Ratio
AAREYDRUGS has a lower P/B
1.46x vs 3.01x
EPS
AAREYDRUGS has higher earnings per share
₹1.47 vs ₹-2.45
Dividend Yield
PPLPHARMA has a higher dividend yield
0.08% vs 0%
Revenue Growth (TTM YoY)
AAREYDRUGS has faster revenue growth
19.8% vs -0.1%
EPS Growth (TTM YoY)
PPLPHARMA has faster EPS growth
0% vs -41.05%
Qtr Sales Growth
AAREYDRUGS has stronger quarterly sales growth
0% vs -0.08%

Each difference is a single, relative reading — StockeZee does not name an overall winner.

Profile

MetricAAREYDRUGSPPLPHARMA
SectorHealthcareHealthcare
IndustryPharmaceuticalsPharmaceuticals

Price

MetricAAREYDRUGSPPLPHARMA
Live Price₹90.51₹177.12
Day Change-4.92%-4.16%
Volume2.2 L79.55 L
52-Week High₹96₹212.39
52-Week Low₹50.31₹132.3
Distance from 52W High-5.72%-16.61%

Valuation

MetricAAREYDRUGSPPLPHARMA
Market Cap₹221 Cr₹23,554 Cr
P/E Ratio55.36x-75.43x
P/B Ratio1.46x3.01x
EPS₹1.47₹-2.45
Book Value₹48.67₹64.78
Dividend Yield0%0.08%

Growth

MetricAAREYDRUGSPPLPHARMA
Revenue Growth (TTM YoY)19.8%-0.1%
EPS Growth (TTM YoY)-41.05%0%
Qtr Sales Growth0%-0.08%
Qtr Profit Growth0%-25%

Profitability & Leverage

MetricAAREYDRUGSPPLPHARMA
ROE2.64%-3.83%
ROCE6%2.52%
Net Margin0.84%-3.68%
Operating Margin2.21%10.4%
Debt to Equity0.33x0.7x

Shareholding

As of Mar 2026 • change vs previous quarter
MetricAAREYDRUGSPPLPHARMA
Promoter Holding37.71% 1.35 pp34.86%
FII Holding4.18% 0.32 pp30.18% 0.52 pp
DII Holding1.62% 1.62 pp15.61% 0.08 pp
Public Holding56.49% 0.6 pp19.01% 0.34 pp

How to Read This Comparison

Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.

Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: Aarey Drugs & Pharmaceuticals Limited and Piramal Pharma Limited.

Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.